TNFSF10 and glioblastoma: To determine whether the TRAIL-modification strategy was suitable to facilitate targeted therapy of oncolytic adenovirus for glioblastoma, we first analyzed the mRNA expression of TRAIL-related death receptors using the TCGA dataset (Figure 4A).